GenoMed Seeks Volunteers for Possible Multiple Sclerosis Treatment
ST. LOUIS, Jan. 21 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based genomics company, announced today that it is seeking volunteers with multiple sclerosis (MS) to test a new medication to be taken in addition to their current medications.
GenoMed has discovered that an extremely safe class of drugs called ACE inhibitors may be useful for many serious diseases, including MS. ACE stands for "angiotensin converting enzyme."
GenoMed found that patients with MS tend to have overactivity of their ACE enzyme. A logical approach is to inhibit ACE. ACE is located on the surface of two classes of cells important in MS: T cells, which direct an autoimmune attack on brain white matter (the sheaths of nerve cells), and the nerve cells themselves.
The research supporting this new treatment approach was published in October, 2002 in Diabetes Technology and Therapeutics.
About GenoMed
GenoMed is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease.
To volunteer, please contact GenoMed's Chief Medical Officer, Dr. David Moskowitz, tel. 314-977-0110, fax 928-395-2580, email: dwmoskowitz@genomedics.com or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Dr. David Moskowitz, of GenoMed, Inc., +1-314-977-0110, or fax,
+1-928-395-2580, or dwmoskowitz@genomedics.com/
Web site: genomedics.com |
